Managing Director Paul Anderson provides valuable insights the company's breakthrough regenerative medicine products, it's strong position within a large and growing market, and its compelling clinical trial results.

Orthocell Limited (ASX: OCC) is a world-leading regenerative medicine company providing innovative products to restore mobility, function and performance.

Any advice contained within this presentation is general advice and does not consider your objectives, financial situation or needs, and you should consider whether it’s appropriate for you. The information we are giving you is for educational purposes only.

Accurate time of recording, 23 September 2020 at 12pm AEST.